Fisher Asset Management LLC Has $22.73 Million Stock Position in Amgen Inc. (NASDAQ:AMGN)

Fisher Asset Management LLC lifted its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 4.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 78,929 shares of the medical research company’s stock after purchasing an additional 3,225 shares during the period. Fisher Asset Management LLC’s holdings in Amgen were worth $22,733,000 as of its most recent filing with the SEC.

Other hedge funds also recently modified their holdings of the company. OFI Invest Asset Management bought a new stake in Amgen during the third quarter valued at $26,000. Briaud Financial Planning Inc bought a new position in shares of Amgen during the 3rd quarter worth approximately $26,000. BOK Financial Private Wealth Inc. bought a new stake in shares of Amgen in the 4th quarter valued at $29,000. Providence Capital Advisors LLC acquired a new stake in Amgen in the third quarter worth $30,000. Finally, Planned Solutions Inc. bought a new stake in Amgen in the fourth quarter valued at $30,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Price Performance

AMGN opened at $311.29 on Monday. The firm has a 50-day moving average price of $274.95 and a 200-day moving average price of $281.46. Amgen Inc. has a twelve month low of $211.71 and a twelve month high of $329.72. The company has a quick ratio of 1.13, a current ratio of 1.65 and a debt-to-equity ratio of 10.14. The company has a market capitalization of $166.97 billion, a price-to-earnings ratio of 44.47, a PEG ratio of 3.01 and a beta of 0.60.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Thursday, May 2nd. The medical research company reported $3.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.76 by $0.20. Amgen had a return on equity of 145.62% and a net margin of 12.74%. The company had revenue of $7.45 billion for the quarter, compared to analyst estimates of $7.45 billion. During the same period in the previous year, the company posted $3.98 EPS. The firm’s revenue for the quarter was up 22.0% compared to the same quarter last year. Equities analysts expect that Amgen Inc. will post 19.46 EPS for the current year.

Amgen Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 17th will be issued a dividend of $2.25 per share. This represents a $9.00 dividend on an annualized basis and a yield of 2.89%. The ex-dividend date is Thursday, May 16th. Amgen’s dividend payout ratio (DPR) is presently 128.57%.

Analyst Ratings Changes

Several analysts have recently commented on the company. Raymond James began coverage on Amgen in a research note on Thursday, March 28th. They issued a “market perform” rating for the company. Royal Bank of Canada cut their target price on Amgen from $332.00 to $328.00 and set an “outperform” rating on the stock in a report on Friday. Truist Financial reiterated a “buy” rating and set a $320.00 price objective on shares of Amgen in a report on Friday, April 12th. William Blair raised shares of Amgen from a “market perform” rating to an “outperform” rating in a research report on Friday. Finally, StockNews.com raised Amgen from a “hold” rating to a “buy” rating in a research note on Friday. Ten investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $305.05.

Insider Buying and Selling at Amgen

In related news, SVP Nancy A. Grygiel sold 2,117 shares of Amgen stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $313.09, for a total transaction of $662,811.53. Following the completion of the sale, the senior vice president now owns 9,883 shares of the company’s stock, valued at $3,094,268.47. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 0.46% of the company’s stock.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.